Mental health care in England is predominantly delivered in community settings, yet pharmacy provision has historically remained concentrated in inpatient services. This mismatch has created a persistent safety gap for people with severe mental illness, particularly those prescribed high‑risk psychotropic medicines such as clozapine and depot antipsychotics. As pressures on community mental health services continue to intensify, addressing this gap is no longer optional — it is a patient safety imperative.
At Kent and Medway Mental Health NHS Trust, we have embedded pharmacists and pharmacy technicians into all nine community mental health teams (CMHTs), creating one of the first trust‑wide, fully integrated community mental health pharmacy models. The impact on medicines safety, continuity of care and multidisciplinary working has been substantial.
Prior to implementation, audits highlighted fragmented medication histories, inconsistent side‑effect monitoring, delays in clozapine initiation and limited access to specialist medicines advice within CMHTs. Patients reported uncertainty about the purpose and risks of their medicines, while clinicians faced increasing workload and risk associated with complex prescribing decisions. These challenges are not unique to our locality and reflect a national structural issue in mental health pharmacy provision.
Embedding pharmacy professionals directly within CMHTs has enabled routine, structured medication reviews, robust side‑effect monitoring using the Glasgow Antipsychotic Side Effect Scale, safer medication reconciliation across care interfaces and significantly improved collaboration with primary care colleagues. Importantly, it has also enabled safe initiation and re‑titration of clozapine in community settings, reducing avoidable admissions and improving access for patients who may otherwise disengage from inpatient pathways.
The benefits have been measurable. Thousands of pharmacist‑led medication reviews have released substantial medical capacity, improved prescribing quality and reduced waiting times. Side‑effect monitoring compliance has reached consistently high levels, with severe adverse effects identified early and acted upon promptly. Patients report high satisfaction with enhanced medicines education, shared decision‑making and implementation of less invasive clozapine monitoring approaches such as capillary blood sampling. Staff across disciplines report improved confidence, reduced workload and stronger multidisciplinary collaboration.
Crucially, this model was delivered without national ring‑fenced funding for mental health pharmacy posts. Success depended on framing pharmacy integration as a system‑level safety and population health intervention, aligned with ‘NHS long term plan’ priorities and community mental health transformation. This strategic positioning was instrumental in securing local investment and demonstrates that workforce redesign in mental health pharmacy is both achievable and sustainable when safety outcomes are clearly articulated.
As the NHS seeks to reduce health inequalities and medicines‑related harm among people with severe mental illness — a group with markedly poorer physical health outcomes — community mental health pharmacy must be viewed as core infrastructure rather than an enhancement. The evidence from our experience suggests that embedding pharmacy professionals within CMHTs delivers safer care, better patient experience and improved system efficiency, while providing a scalable blueprint for wider national adoption.
The question is no longer whether CMHTs can afford dedicated pharmacy input but whether they can afford to continue without it.
Tayo Bella, advanced lead community mental health team pharmacist, Kent and Medway Mental Health NHS Trust
You may also be interested in
Medical cannabis not effective as a mental health treatment, finds meta analysis
Specialist mental health pharmacist clinics in primary care: a service evaluation supporting integrated neighbourhood working
